Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit.

BACKGROUND Studies that have evaluated the use of intravenous vitamin C in adults with sepsis who were receiving vasopressor therapy in the intensive care unit (ICU) have shown mixed results with respect to the risk of death and organ dysfunction. METHODS In this randomized, placebo-controlled trial, we assigned adults who had been in the ICU for no longer than 24 hours, who had proven or suspected infection as the main diagnosis, and who were receiving a vasopressor to receive an infusion of either vitamin C (at a dose of 50 mg per kilogram of body weight) or matched placebo administered every 6 hours for up to 96 hours. The primary outcome was a composite of death or persistent organ dysfunction (defined by the use of vasopressors, invasive mechanical ventilation, or new renal-replacement therapy) on day 28. RESULTS A total of 872 patients underwent randomization (435 to the vitamin C group and 437 to the control group). The primary outcome occurred in 191 of 429 patients (44.5%) in the vitamin C group and in 167 of 434 patients (38.5%) in the control group (risk ratio, 1.21; 95% confidence interval [CI], 1.04 to 1.40; P = 0.01). At 28 days, death had occurred in 152 of 429 patients (35.4%) in the vitamin C group and in 137 of 434 patients (31.6%) in the placebo group (risk ratio, 1.17; 95% CI, 0.98 to 1.40) and persistent organ dysfunction in 39 of 429 patients (9.1%) and 30 of 434 patients (6.9%), respectively (risk ratio, 1.30; 95% CI, 0.83 to 2.05). Findings were similar in the two groups regarding organ-dysfunction scores, biomarkers, 6-month survival, health-related quality of life, stage 3 acute kidney injury, and hypoglycemic episodes. In the vitamin C group, one patient had a severe hypoglycemic episode and another had a serious anaphylaxis event. CONCLUSIONS In adults with sepsis receiving vasopressor therapy in the ICU, those who received intravenous vitamin C had a higher risk of death or persistent organ dysfunction at 28 days than those who received placebo. (Funded by the Lotte and John Hecht Memorial Foundation; LOVIT ClinicalTrials.gov number, NCT03680274.).

[1]  A. Zandvliet,et al.  Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens , 2018, Chest.

[2]  G. Guyatt,et al.  Lessening Organ Dysfunction With Vitamin C (LOVIT) Trial: Statistical Analysis Plan , 2022, JMIR research protocols.

[3]  Samuel M. Brown,et al.  Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial. , 2021, JAMA.

[4]  G. Escobar,et al.  Hospital deaths in patients with sepsis from 2 independent cohorts. , 2014, JAMA.

[5]  B. Kahan.  Accounting for centre-effects in multicentre trials with a binary outcome – when, why, and how? , 2014, BMC Medical Research Methodology.

[6]  P. Marik,et al.  Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before‐After Study , 2017, Chest.

[7]  G. Guyatt,et al.  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis , 2002, BMJ : British Medical Journal.

[8]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[9]  R. Bellomo,et al.  Effect of adjunctive vitamin C, glucocorticoids, and vitamin B1 on longer-term mortality in adults with sepsis or septic shock: a systematic review and a component network meta-analysis , 2021, Intensive Care Medicine.

[10]  G. Guyatt,et al.  Lessening Organ dysfunction with VITamin C (LOVIT): protocol for a randomized controlled trial , 2020, Trials.

[11]  A. Fowler,et al.  Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis , 2014, Journal of Translational Medicine.

[12]  L. Trinquart,et al.  Influence of trial sample size on treatment effect estimates: meta-epidemiological study , 2013, BMJ : British Medical Journal.

[13]  I. McDowell,et al.  A global clinical measure of fitness and frailty in elderly people , 2005, Canadian Medical Association Journal.

[14]  A. Day,et al.  Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials , 2011, Critical care.

[15]  R. Woolson,et al.  To condition or not condition? Analysing ‘change’ in longitudinal randomised controlled trials , 2016, BMJ Open.

[16]  J. Richards,et al.  Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. , 1993, BMJ.

[17]  R. Varadhan,et al.  Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses , 2020, Canadian Medical Association Journal.

[18]  A. Carr,et al.  Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes , 2017, Critical Care.

[19]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[20]  Norbert Lameire,et al.  Notice , 2012, Kidney International Supplements.

[21]  N. Adhikari,et al.  High-dose vitamin-C induced prolonged factitious hyperglycemia in a peritoneal dialysis patient: a case report , 2021, Journal of Medical Case Reports.

[22]  G. Guyatt,et al.  Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. , 2007, Journal of clinical epidemiology.

[23]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[24]  G. Martin,et al.  Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. , 2019, JAMA.

[25]  M. Berger,et al.  Vitamin therapy in critically ill patients: focus on thiamine, vitamin C, and vitamin D , 2018, Intensive Care Medicine.